Microbial Metabolites as Therapeutic Targets


Microbial Metabolites as Therapeutic Targets

The human gastrointestinal tract is colonized by a dense population of microbes of bacteria, viruses and microbial eukaryotes and form the communities that are referred as the gut microbiota, which plays a pivotal role in maintaining host homeostasis, while commensal microbes can also engage in disease processes through physical interactions or through secreted molecules that gain access to the systemic circulation. Gastrointestinal microbiota produces or modulates versatility of functional metabolites, in recent decades, microbial metabolites have attracted increasing interest as probes for physiological mechanisms and potential targets for therapeutics, owing to their properties such as pervasiveness, functional pleiotropy, ease of administration, and tissue bioavailability, and numerous challenges will have to be met and overcome on developing new therapies based on microbiota-derived metabolites, where the potential is enormous.

The progress of using microbes to treat human diseases - Bacterial Macromolecules as Therapeutic Targets

Figure 1. The beneficial (green) or detrimental (red) role of gut microbiota-derived metabolites in disease. (Descamps 2019)

Creative Proteomics is a preeminent corporation that specializes in multi-omics. Equipped with cutting-edge techniques and served by well-experienced scientists, we have extensive experience to assist you in the microbial metabolites as therapeutic targets research and provide abundant research solutions into every aspect from the fundamental mechanism studies to therapeutics development, and assist you in analyzing the methodology, clinical decision, and features including safety and efficacy, to help you make decisive breakthroughs in microbial metabolites as therapeutic targets research.

We provide one-stop solutions for the untargeted metabolomics profiling approach and the targeted metabolomics profiling approach, which cover the entire workflow including sample preparation, metabolite separation, detection, and data analysis and interpretation, as well as developing corresponding therapies targeting these microbial metabolites. Here are some types of metabolites that are within our power and may have potential working as therapeutic targets:

Trimethylamine-N-oxide (TMAO)
Short-chain fatty acids (SCFAs)
Long-chain fatty acids (LCFAs)
4-ethylphenylsulfate (4-EPS)
Retinoic acid
Protein-derived metabolites
Bile acids (BAs)
N-acyl amides

The functions of these metabolites are pleiotropic and highly context-dependent, and the precise therapeutic effect depends on multiple factors. We can assist you in characterizing disease-associated gut microorganisms and their metabolites, identifying and validating microbial metabolite synthesis pathways, discovering physiological effects of microbiota-derived molecules that may serve as therapeutic targets, and overcoming all kinds of challenges and obstacles to achieve successful clinical trials.

Creative Proteomics dedicates to providing the highest level of solutions in gut microbiota research. We will offer the most suitable strategies according to your sample and research purpose. Our specialty covers the full range of multi-omics including metagenomics, metatranscriptomics, metaproteomics, and metabolomics, coupled with powerful bioinformatics platforms, and other practical tools and resources, we provide the most comprehensive gut microbiota research solutions you will ever get. To find out more solutions for microbial metabolites as therapeutic targets research, please feel free to contact us.


1. Descamps HC; et al. The path toward using microbial metabolites as therapies. EBioMedicine. 2019, 44:747-54.

For Research Use Only. Not for use in diagnostic procedures.

Online Inquiry

Verification Code